- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT06482853
Effetti cardiovascolari dell'angiotensina-(1-7) nell'ipertensione dovuta all'obesità
Obesity is a global health concern that is associated with high blood pressure and an increased risk for developing cardiovascular disease. The purpose of this study is to find out if the investigational drug angiotensin-(1-7) can improve cardiovascular health in people with obesity and high blood pressure.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
A randomized, double blind, placebo controlled, crossover study will be conducted to determine if acute intravenous angiotensin-(1-7) infusion reduces cardiovascular sympathetic tone and blood pressure and improves the function of blood vessels in participants with obesity hypertension. This is an outpatient study that requires a screening visit, and if eligible, two study visits separated by at least one week in the Clinical Research Center within the Penn State Milton S. Hershey Medical Center. The study visits will include intravenous infusion of angiotensin-(1-7) or saline for approximately two hours, starting with increasing doses and holding at a steady-state dose. Endothelial function will be measured and blood samples collected at baseline and at the end of infusion. Blood pressure, heart rate, and muscle sympathetic nerve activity (via microneurography) will be measured continuously throughout the study. Each study visit will last approximately 4 hours.
Tipo di studio
Iscrizione (Stimato)
Fase
- Prima fase 1
Contatti e Sedi
Contatto studio
- Nome: Aimee Cauffman, RN
- Numero di telefono: 717-531-1617
- Email: acauffman@pennstatehealth.psu.edu
Backup dei contatti dello studio
- Nome: Amy Arnold, PhD
- Numero di telefono: 717-531-3674
- Email: aarnold5@pennstatehealth.psu.edu
Luoghi di studio
-
-
Pennsylvania
-
Hershey, Pennsylvania, Stati Uniti, 17033
- Reclutamento
- Penn State Milton S. Hershey Medical Center
-
Sub-investigatore:
- Urs A Leuenberger, MD
-
Sub-investigatore:
- Aimee Cauffman, RN
-
Sub-investigatore:
- Cheryl Blaha, RN
-
Sub-investigatore:
- Jian Cui, PhD
-
Contatto:
- Amy Arnold, PhD
- Numero di telefono: 717-531-3674
- Email: aarnold5@pennstatehealth.psu.edu
-
Sub-investigatore:
- Takuto Hamaoka, MD, PhD
-
Sub-investigatore:
- Mami Hamaoka, MD
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Men and women of all races
- Age 18 to 65 years
- Body mass index (BMI) between 30-45 kg/m2
- Pre-hypertension (defined as two or more seated blood pressure readings >120/80 mmHg) or hypertension (defined as two or more seated blood pressure readings >130/80 mmHg or use of antihypertensive medications)
- Capable of giving informed consent
- Fluent in written and spoken English
- Satisfactory history and physical exam
Exclusion Criteria:
- Age ≤ 17 or ≥ 66 years
- Taking more than two antihypertensive medications
- Secondary causes of hypertension (e.g., pheochromocytoma, primary aldosteronism, aortic coarctation, adrenal disease)
- Pregnant or nursing women
- Women taking hormone replacement therapy within 6 months
- Decisional impairment
- Prisoners
- Alcohol or drug abuse
- Current smokers
- Highly trained athletes
- Subjects with >5% weight change in the past 3 months
- BMI > 45 kg/m2
- Evidence of type I or type II diabetes (fasting glucose > 126 mg/dL or use of anti-diabetic medications)
- History of serious cardiovascular disease (e.g. myocardial infarction within 6 months, symptomatic coronary artery disease, presence of angina pectoris, significant arrhythmia, congestive heart failure, deep vein thrombosis, pulmonary embolism, second or third degree heart block, mitral valve stenosis, aortic stenosis, hypertrophic cardiomyopathy) or cerebrovascular disease (e.g. cerebral hemorrhage, stroke, transient Ischemic attack)
- History or presence of immunological or hematological disorders
- Impaired hepatic function [aspartate aminotransferase (AST) or alanine transaminase (ALT) levels >2 times upper limit of normal range]
- Impaired renal function (serum creatinine >2.0 mg/dl)
- Anemia
- Treatment with drugs increasing sympathetic activity [e.g., serotonin-norepinephrine reuptake inhibitors (SNRIs) or norepinephrine transporter (NET) inhibitors, stimulants]
- Treatment with phosphodiesterase-5 inhibitors
- Treatment with anticoagulants (e.g. warfarin)
- Treatment with chronic systemic glucocorticoid therapy (>7 consecutive days in 1 month)
- Treatment with any investigational drug in the 1-month preceding the study
- Inability to give, or withdraw, informed consent
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Scienza basilare
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione incrociata
- Mascheramento: Doppio
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Angiotensin-(1-7)
Participants will receive intravenous angiotensin-(1-7) at one study visit for a total of 120 minutes. Angiotensin-(1-7) will be given in escalating doses of 2 ng/kg/min, 4 ng/kg/min, and 8 ng/kg/min. Each of these doses will be infused for 10 minutes. Following this 30 minute dose escalation period, angiotensin-(1-7) will be given at 8 ng/kg/min for an additional 90 minutes. Infusion rates will be calculated for each patient based on body mass. |
This is a biologically active endogenous angiotensin peptide that may play an important role in regulation of blood pressure.
Altri nomi:
|
|
Comparatore placebo: Saline
Participants receive intravenous saline at one study visit for a total of 120 minutes. The volume of saline will match the volume of angiotensin-(1-7) infused. Infusion rates will be calculated for each patient based on body mass. |
Saline will be used as the placebo comparator.
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change in Muscle Sympathetic Nerve Burst Rate
Lasso di tempo: 120 minutes
|
Muscle sympathetic nerve burst rate will be measured continuously using peroneal nerve microneurography during angiotensin-(1-7) versus saline infusion. |
120 minutes
|
|
Change in Brachial Artery Diameter
Lasso di tempo: 120 minutes
|
A blood pressure cuff will be inflated to a suprasystolic pressure for 5 minutes then deflated. Brachial artery diameter will be measured continuously before, during, and after cuff inflation using duplex ultrasound at baseline and at the end of angiotensin-(1-7) versus saline infusion. |
120 minutes
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change in Muscle Sympathetic Nerve Burst Incidence
Lasso di tempo: 120 minutes
|
Muscle sympathetic nerve burst incidence will be measured continuously using peroneal nerve microneurography during angiotensin-(1-7) versus saline infusion. |
120 minutes
|
|
Change in Muscle Sympathetic Nerve Amplitude
Lasso di tempo: 120 minutes
|
Muscle sympathetic nerve amplitude will be measured continuously using peroneal nerve microneurography during angiotensin-(1-7) versus saline infusion. |
120 minutes
|
|
Change in Muscle Sympathetic Nerve Total Activity
Lasso di tempo: 120 minutes
|
Muscle sympathetic nerve total activity will be measured continuously using peroneal nerve microneurography during angiotensin-(1-7) versus saline infusion. |
120 minutes
|
|
Change in Systolic Blood Pressure
Lasso di tempo: 120 minutes
|
Blood pressure will be measured continuously with a finger and arm cuff during angiotensin-(1-7) versus saline infusion. |
120 minutes
|
|
Change in Diastolic Blood Pressure
Lasso di tempo: 120 minutes
|
Blood pressure will be measured continuously with a finger and arm cuff during angiotensin-(1-7) versus saline infusion. |
120 minutes
|
|
Change in Heart Rate
Lasso di tempo: 120 minutes
|
Heart rate will be measured continuously by electrocardiogram during angiotensin-(1-7) versus saline infusion. |
120 minutes
|
|
Change in Plasma Catecholamines
Lasso di tempo: 120 minutes
|
Circulating catecholamine levels will be measured in blood samples obtained at baseline and at the end of angiotensin-(1-7) versus saline infusion. |
120 minutes
|
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change in Angiotensin II
Lasso di tempo: 120 minutes
|
Plasma angiotensin II levels will be measured in blood samples obtained at baseline and at the end of angiotensin-(1-7) versus saline infusion. |
120 minutes
|
|
Change in Angiotensin-(1-7)
Lasso di tempo: 120 minutes
|
Plasma angiotensin-(1-7) levels will be measured in blood samples obtained at baseline and at the end of angiotensin-(1-7) versus saline infusion. |
120 minutes
|
|
Change in Renin Activity
Lasso di tempo: 120 minutes
|
Plasma renin activity will be measured in blood samples obtained at baseline and at the end of angiotensin-(1-7) versus saline infusion. |
120 minutes
|
|
Change in Aldosterone
Lasso di tempo: 120 minutes
|
Plasma or serum aldosterone levels will be measured in blood samples obtained at baseline and at the end of angiotensin-(1-7) versus saline infusion. |
120 minutes
|
|
Change in Heart Rate Variability
Lasso di tempo: 120 minutes
|
Heart rate variability will be calculated from the continuous electrocardiogram recordings obtained during angiotensin-(1-7) versus saline infusion. |
120 minutes
|
|
Change in Baroreflex Sensitivity
Lasso di tempo: 120 minutes
|
Baroreflex sensitivity will be calculated from the continuous blood pressure and electrocardiogram recordings obtained during angiotensin-(1-7) versus saline infusion. |
120 minutes
|
Collaboratori e investigatori
Sponsor
Collaboratori
Investigatori
- Investigatore principale: Amy Arnold, PhD, Pennsylvania State University College of Medicine
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Malattie vascolari
- Malattia cardiovascolare
- Disturbi della nutrizione
- Ipernutrizione
- Peso corporeo
- Sovrappeso
- Condizioni patologiche, segni e sintomi
- Malattie nutrizionali e metaboliche
- Segni e sintomi
- Obesità
- Ipertensione
- Prodotti chimici organici
- Preparati farmaceutici
- Acidi grassi
- Lipidi
- Acidi, aciclici
- Acidi carbossilici
- Prodotti chimici inorganici
- Composti di cloro
- Soluzioni cristalloidi
- Soluzioni isotoniche
- Soluzioni
- Acidi grassi, volatile
- Composti di sodio
- Cloruri
- Acido cloridrico
- Soluzione salina
- Cloruro di sodio
- Acetate
- Angiotensina I (1-7)
Altri numeri di identificazione dello studio
- STUDY 8170-Part 2
- R01HL170140 (Sovvenzione/contratto NIH degli Stati Uniti)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Individual participant data will not be available to other researchers.
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .